Showing posts with label Complete Response Letter. Show all posts
Showing posts with label Complete Response Letter. Show all posts
Tuesday, February 3, 2026

FDA Issues Complete Response Letter for Biohaven's Vyglxia (troriluzole) New Drug Application for Spinocerebellar Ataxia

›
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development a...
Thursday, August 8, 2024

Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults

›
Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced the...
Wednesday, May 1, 2019

FDA Issues Complete Response Letter for Zynquista (sotagliflozin)

›
In continuation of my update on  Zynquista ( sotagliflozin )   The U.S. Food and Drug Administration (FDA) issu ed a Complete Resp...
Wednesday, March 13, 2019

Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)

›
  Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Let...
Tuesday, November 13, 2018

Sunovion receives Complete Response Letter from FDA for dasotraline NDA

›
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Lette...